| +1.90 / +10.91%|
The 13 analysts offering 12-month price forecasts for Sarepta Therapeutics Inc have a median target of 20.00, with a high estimate of 52.00 and a low estimate of 10.00. The median estimate represents a +3.57% increase from the last price of 19.31.
The current consensus among 16 polled investment analysts is to Hold stock in Sarepta Therapeutics Inc. This rating has held steady since November, when it was downgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.